Lisjak D, Arcon I, Poberznik M, Herrero-Saboya G, Tufani A, Mavric A
Sci Rep. 2023; 13(1):1092.
PMID: 36658162
PMC: 9852462.
DOI: 10.1038/s41598-023-28431-4.
Djanis J, Princic G, Mavric A, Mertelj A, Iskra J, Lisjak D
Nanomaterials (Basel). 2022; 12(12).
PMID: 35745462
PMC: 9229317.
DOI: 10.3390/nano12122123.
Delille F, Pu Y, Lequeux N, Pons T
Cancers (Basel). 2022; 14(10).
PMID: 35626059
PMC: 9139368.
DOI: 10.3390/cancers14102456.
Barosi A, Dunkel P, Guenin E, Lalatonne Y, Zeitoun P, Fitton I
RSC Adv. 2022; 10(6):3366-3370.
PMID: 35497736
PMC: 9048766.
DOI: 10.1039/c9ra09828c.
Lisjak D, Hribar Bostjancic P, Mertelj A, Mavric A, Valant M, Kovac J
ACS Omega. 2020; 5(23):14086-14095.
PMID: 32566875
PMC: 7301540.
DOI: 10.1021/acsomega.0c01597.
Synthesis and modification of uniform PEG-neridronate-modified magnetic nanoparticles determines prolonged blood circulation and biodistribution in a mouse preclinical model.
Patsula V, Horak D, Kucka J, Mackova H, Lobaz V, Francova P
Sci Rep. 2019; 9(1):10765.
PMID: 31341232
PMC: 6656745.
DOI: 10.1038/s41598-019-47262-w.
Hybrid Au@alendronate nanoparticles as dual chemo-photothermal agent for combined cancer treatment.
Sangnier A, Aufaure R, Motte L, Wilhelm C, Guenin E, Lalatonne Y
Beilstein J Nanotechnol. 2018; 9:2947-2952.
PMID: 30546991
PMC: 6278761.
DOI: 10.3762/bjnano.9.273.
Biocompatible coated magnetosome minerals with various organization and cellular interaction properties induce cytotoxicity towards RG-2 and GL-261 glioma cells in the presence of an alternating magnetic field.
Hamdous Y, Chebbi I, Mandawala C, Le Fevre R, Guyot F, Seksek O
J Nanobiotechnology. 2017; 15(1):74.
PMID: 29041937
PMC: 5646109.
DOI: 10.1186/s12951-017-0293-2.
Iron Oxide Nanoparticles Coated with a Phosphorothioate Oligonucleotide and a Cationic Peptide: Exploring Four Different Ways of Surface Functionalization.
Geinguenaud F, Banissi C, Carpentier A, Motte L
Nanomaterials (Basel). 2017; 5(4):1588-1609.
PMID: 28347083
PMC: 5304778.
DOI: 10.3390/nano5041588.
Towards potential nanoparticle contrast agents: Synthesis of new functionalized PEG bisphosphonates.
Kachbi-Khelfallah S, Monteil M, Cortes-Clerget M, Migianu-Griffoni E, Pirat J, Gager O
Beilstein J Org Chem. 2016; 12:1366-71.
PMID: 27559386
PMC: 4979661.
DOI: 10.3762/bjoc.12.130.
Purification of a low molecular weight fucoidan for SPECT molecular imaging of myocardial infarction.
Saboural P, Chaubet F, Rouzet F, Al-Shoukr F, Ben Azzouna R, Bouchemal N
Mar Drugs. 2014; 12(9):4851-67.
PMID: 25251032
PMC: 4178488.
DOI: 10.3390/md12094851.
Bisphosphonates and cancer: what opportunities from nanotechnology?.
De Rosa G, Misso G, Salzano G, Caraglia M
J Drug Deliv. 2013; 2013:637976.
PMID: 23533771
PMC: 3603225.
DOI: 10.1155/2013/637976.
Bisphosphonate-anchored PEGylation and radiolabeling of superparamagnetic iron oxide: long-circulating nanoparticles for in vivo multimodal (T1 MRI-SPECT) imaging.
Sandiford L, Phinikaridou A, Protti A, Meszaros L, Cui X, Yan Y
ACS Nano. 2012; 7(1):500-12.
PMID: 23194247
PMC: 3953894.
DOI: 10.1021/nn3046055.
Synthesis of 64Cu(II)-bis(dithiocarbamatebisphosphonate) and its conjugation with superparamagnetic iron oxide nanoparticles: in vivo evaluation as dual-modality PET-MRI agent.
Torres Martin de Rosales R, Tavare R, Paul R, Jauregui-Osoro M, Protti A, Glaria A
Angew Chem Int Ed Engl. 2011; 50(24):5509-13.
PMID: 21544908
PMC: 3179845.
DOI: 10.1002/anie.201007894.
(⁹⁹m)Tc-bisphosphonate-iron oxide nanoparticle conjugates for dual-modality biomedical imaging.
Torres Martin de Rosales R, Tavare R, Glaria A, Varma G, Protti A, Blower P
Bioconjug Chem. 2011; 22(3):455-65.
PMID: 21338098
PMC: 6205601.
DOI: 10.1021/bc100483k.
Superparamagnetic bifunctional bisphosphonates nanoparticles: a potential MRI contrast agent for osteoporosis therapy and diagnostic.
Lalatonne Y, Monteil M, Jouni H, Serfaty J, Sainte-Catherine O, Lievre N
J Osteoporos. 2010; 2010:747852.
PMID: 20981332
PMC: 2957199.
DOI: 10.4061/2010/747852.
